Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights
Arcadia Biosciences (NASDAQ:RKDA) reported Q2 2025 financial results, with total revenues increasing 11% year-over-year to $1.46 million, driven by 24% growth in Zola® coconut water sales. The company maintained gross margins above 30% for ten consecutive quarters.
Key developments include receiving 2.7 million shares of Above Food Ingredients (ABVE) stock as partial repayment of a $6 million note receivable from the GoodWheat™ assets sale, and eliminating $1 million in contingent liabilities through an agreement with Bioseed Research India. However, the company recognized a $4.5 million credit loss related to the Above Food note receivable.
Q2 2025 resulted in a net loss of $4.46 million ($3.26 per share), compared to net income of $1.06 million in Q2 2024. The company's pending business combination with Roosevelt Resources continues to progress with an amended Form S-4 registration statement filed.
Arcadia Biosciences (NASDAQ:RKDA) ha comunicato i risultati finanziari del secondo trimestre 2025: i ricavi totali sono saliti dell'11% su base annua, raggiungendo $1,46 milioni, sostenuti da un aumento del 24% nelle vendite dell'acqua di cocco Zola®. L'azienda ha mantenuto margini lordi superiori al 30% per dieci trimestri consecutivi.
Tra gli avvenimenti principali, Arcadia ha ricevuto 2,7 milioni di azioni di Above Food Ingredients (ABVE) come parziale rimborso di un prestito di $6 milioni derivante dalla cessione degli asset GoodWheat™, e ha eliminato $1 milione di passività eventuali tramite un accordo con Bioseed Research India. Tuttavia, ha registrato una perdita per crediti di $4,5 milioni relativa al credito verso Above Food.
Il Q2 2025 si è chiuso con una perdita netta di $4,46 milioni ($3,26 per azione), rispetto a un utile netto di $1,06 milioni nel Q2 2024. Prosegue lo sviluppo della combinazione aziendale proposta con Roosevelt Resources, con la presentazione di una versione emendata del modulo di registrazione Form S-4.
Arcadia Biosciences (NASDAQ:RKDA) presentó sus resultados financieros del segundo trimestre de 2025: los ingresos totales aumentaron un 11% interanual hasta $1,46 millones, impulsados por un crecimiento del 24% en las ventas de agua de coco Zola®. La compañía mantuvo márgenes brutos por encima del 30% durante diez trimestres consecutivos.
Entre las novedades, recibió 2,7 millones de acciones de Above Food Ingredients (ABVE) como pago parcial de un pagaré de $6 millones relacionado con la venta de los activos GoodWheat™, y canceló $1 millón en pasivos contingentes mediante un acuerdo con Bioseed Research India. No obstante, registró una pérdida por crédito de $4,5 millones vinculada al pagaré de Above Food.
El Q2 2025 cerró con una pérdida neta de $4,46 millones ($3,26 por acción), frente a una ganancia neta de $1,06 millones en el Q2 2024. Continúa avanzando la potencial fusión con Roosevelt Resources, con la presentación enmendada del formulario de registro Form S-4.
Arcadia Biosciences (NASDAQ:RKDA)는 2025 회계연도 2분기 실적을 발표했습니다. 총수익은 전년 대비 11% 증가한 $1.46백만을 기록했으며, 이는 Zola® 코코넛 워터 매출이 24% 성장한 데 힘입은 것입니다. 회사는 10분기 연속으로 총마진을 30% 이상 유지했습니다.
주요 내용으로는 GoodWheat™ 자산 매각과 관련된 600만 달러의 수취채권 일부 상환으로 Above Food Ingredients(ABVE) 주식 270만 주를 수령했고, Bioseed Research India와의 합의를 통해 100만 달러의 우발부채를 해소했습니다. 다만 Above Food 수취채권과 관련해 450만 달러의 대손상각을 인식했습니다.
2분기 순손실은 $4.46백만(주당 $3.26)으로, 2024년 2분기의 순이익 $1.06백만과 대비됩니다. Roosevelt Resources와의 잠재적 기업결합은 계속 진행 중이며, 수정된 Form S-4 등록서류가 제출되었습니다.
Arcadia Biosciences (NASDAQ:RKDA) a publié ses résultats du deuxième trimestre 2025 : les revenus totaux ont augmenté de 11% en glissement annuel pour atteindre $1,46 million, portés par une croissance de 24% des ventes d'eau de coco Zola®. La société a maintenu des marges brutes supérieures à 30% pendant dix trimestres consécutifs.
Parmi les faits marquants, Arcadia a reçu 2,7 millions d'actions d'Above Food Ingredients (ABVE) en remboursement partiel d'une créance de $6 millions liée à la vente des actifs GoodWheat™, et a éliminé $1 million de passifs éventuels via un accord avec Bioseed Research India. Toutefois, elle a enregistré une perte sur créances de $4,5 millions liée à la créance envers Above Food.
Le 2e trimestre 2025 s'est soldé par une perte nette de $4,46 millions (soit $3,26 par action), contre un bénéfice net de $1,06 million au 2e trimestre 2024. La fusion envisagée avec Roosevelt Resources progresse, avec le dépôt d'une version amendée du formulaire d'enregistrement Form S-4.
Arcadia Biosciences (NASDAQ:RKDA) meldete die Finanzergebnisse für das zweite Quartal 2025: Die Gesamtumsätze stiegen im Jahresvergleich um 11% auf $1,46 Millionen, getragen von einem 24%igen Wachstum der Zola®-Kokosnusswasser-Verkäufe. Das Unternehmen hielt die Bruttomargen zehn Quartale in Folge über 30%.
Wesentliche Entwicklungen: Als Teilrückzahlung einer $6 Millionen Forderung aus dem Verkauf der GoodWheat™-Aktiva erhielt Arcadia 2,7 Millionen Aktien von Above Food Ingredients (ABVE) und konnte durch eine Vereinbarung mit Bioseed Research India $1 Million an Eventualverbindlichkeiten beseitigen. Gleichzeitig wurde jedoch ein Forderungsausfall in Höhe von $4,5 Millionen im Zusammenhang mit der Above Food-Forderung verbucht.
Das Q2 2025 schloss mit einem Nettoverlust von $4,46 Millionen ($3,26 pro Aktie), gegenüber einem Nettogewinn von $1,06 Millionen im Q2 2024. Die geplante Fusion mit Roosevelt Resources schreitet voran; eine geänderte Form S-4-Registrierung wurde eingereicht.
- Zola coconut water revenues grew 24% in Q2 2025
- Total revenues increased 11% year-over-year to $1.46 million
- Gross margins maintained above 30% for ten consecutive quarters
- Eliminated $2 million in total liabilities year-to-date
- Received 2.7 million shares of ABVE stock as partial debt repayment
- Recognized $4.5 million credit loss on Above Food note receivable
- Net loss of $4.46 million in Q2 2025 compared to $1.06 million profit in Q2 2024
- Operating expenses increased by $2.63 million year-over-year
- Cost of revenues increased 30% in Q2 2025
- Above Food failed to make first payment of principal and accrued interest due May 14, 2025
Insights
Arcadia shows mixed Q2 results with 11% revenue growth but $4.5M credit loss resulting in significant net loss position.
Arcadia's Q2 results present a complex financial picture with both strengths and challenges. The company achieved 11% year-over-year revenue growth to
However, beneath these positive top-line metrics lies concerning financial strain. The company reported a net loss of
The company's total operating expenses increased dramatically to
On the positive side, Arcadia has successfully streamlined operations by exiting legacy businesses and reducing SG&A costs by
-- Arcadia revenues increase
-- Arcadia receives 2.7 million shares of stock in ABVE --
-- Arcadia eliminates
DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025.
“We are very pleased with our performance for the second quarter of 2025,” said T.J. Schaefer, CEO of Arcadia. “While our total revenues have increased
“In addition to our strong operating performance, we received 2.7 million shares of stock in Above Food Ingredients Inc. as a partial repayment of the
“Our pending business combination with Roosevelt Resources continues to move forward,” Schaefer continued. “We recently filed an amendment to the initial Form S-4 registration statement to provide responses to comments received from the SEC and to provide updated financial information through the first quarter of 2025 for both Arcadia Biosciences and Roosevelt Resources.”
| Arcadia Biosciences, Inc. Financial Snapshot (Unaudited) ($ in thousands) | ||||||||||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
| 2025 | 2024 | Favorable/ (Unfavorable) | 2025 | 2024 | Favorable/ (Unfavorable) | |||||||||||||||||||
| $ | % | $ | % | |||||||||||||||||||||
| Total revenues | 1,455 | 1,306 | 149 | 11 | % | 2,655 | 2,293 | 362 | 16 | % | ||||||||||||||
| Total operating expenses | 1,956 | (674 | ) | (2,630 | ) | (390 | %) | 2,626 | 1,901 | (725 | ) | (38 | %) | |||||||||||
| (Loss) income from continuing operations | (501 | ) | 1,980 | (2,481 | ) | (125 | %) | 29 | 392 | (363 | ) | (93 | %) | |||||||||||
| Net (loss) income attributable to common stockholders | (4,458 | ) | 1,061 | (5,519 | ) | (520 | %) | (1,859 | ) | (1,362 | ) | (497 | ) | (36 | %) | |||||||||
Certain previously reported financial information has been reclassified to conform to the current year presentation. Reclassifications are related to the presentation of the financial results of our former GoodWheat™ brand as discontinued operations. The financial information above and narrative that follows relate to continuing operations unless stated otherwise.
More detailed financial information is included in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), available in the Investors section of the company’s website under SEC Filings.
Revenues
Revenues increased
Revenues increased
Arcadia did not implement any price increases during 2024 or the first half of 2025.
Operating Expenses
Cost of revenues increased
Cost of revenues increased by
SG&A decreased by
Other operating expenses increased by
Other operating expenses increased by
Credit Loss and Common Stock Received
On May 1, 2025, Arcadia delivered a notice to Above Food Corp. to exercise a stock election option provided for in their Promissory Note related to the sale of GoodWheat assets in the second quarter of 2024. The notice indicated that pursuant to the provisions of the Promissory Note, the number of shares issuable was approximately 3.5 million shares of common stock of Above Food Ingredients Inc. (ABVE), satisfying the final
Additionally, the first payment of principal and accrued interest under the Promissory Note was due on May 14, 2025, and as of June 30, 2025, had not been paid. As such, Arcadia has recognized a credit loss of
Net Loss Attributable to Common Stockholders
Net loss attributable to common stockholders for the second quarter of 2025 was
Net loss attributable to common stockholders for the first half of 2025 was
Conference Call
In light of the ongoing transaction with Roosevelt Resources and the recently filed Registration Statement (initially filed with the SEC on February 14, 2025, and amended July 31, 2025), the company will not hold a conference call to discuss second quarter results.
About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about the company and its products, including statements relating to the company’s growth, cash position, operating costs, financial performance, commercialization of products, strategic transactions, our ability to obtain sufficient funding required to continue our operations and planned activities, our ability to obtain the stockholder approvals required to complete the proposed business combination transaction with Roosevelt and to satisfy the closing conditions contained in the agreements relating to the transaction, the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the proposed business combination transaction, and the anticipated timing of the closing of the proposed business combination transaction with Roosevelt Resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2024 as amended, the registration statement on Form S-4 initially filed with the SEC on February 14, 2025 and amended July 31, 2025, and other filings that the company makes with the SEC. These forward-looking statements speak only as of the date hereof, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
No Offer or Solicitation
As previously reported on a Report on Form 8-K filed by the company with the SEC, on December 4, 2024, the company, Roosevelt Resources, LP, a Texas limited partnership, and certain other parties entered into a Securities Exchange Agreement (as the same may be amended, the Exchange Agreement) providing for the combination of the two companies in an all-stock transaction. Under the terms of the Exchange Agreement, at the closing of the transactions contemplated by the Exchange Agreement, Arcadia will issue to the partners of Roosevelt shares of Arcadia common stock in exchange for all of the equity interests in Roosevelt.
This press release, including the information contained herein, is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.
Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, no offer will be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.
Additional Information for Stockholders
In connection with the proposed transaction, Arcadia intends to file relevant materials with the SEC and previously filed a Registration Statement on Form S-4 that includes a preliminary proxy statement/prospectus, with the SEC on February 14, 2025, and filed a pre-effective amendment to the Registration Statement on July 31, 2025. After the Registration Statement is declared effective by the SEC, Arcadia intends to mail a definitive proxy statement/prospectus to the stockholders of Arcadia relating to a meeting of stockholders to consider matters relating to the proposed transaction and other matters. This press release is not a substitute for the proxy statement/ prospectus or the Registration Statement or for any other document that Arcadia may file with the SEC and send to Arcadia’s stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF ARCADIA ARE URGED TO CAREFULLY AND THOROUGHLY READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS FILED BY ARCADIA WITH THE SEC, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARCADIA, ROOSEVELT, THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO AND RELATED MATTERS.
Investors will be able to obtain free copies of the Registration Statement and proxy statement/prospectus, as each may be amended from time to time, and other relevant documents filed by Arcadia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed with the SEC by Arcadia will be available free of charge from Arcadia’s website at www.arcadiabio.com under the “Investors” tab. In addition, investors and stockholders should note that Arcadia communicates with investors and the public using its website. Stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transactions.
Participants in the Proxy Solicitation
Arcadia, Roosevelt and their respective directors, partners and certain of their officers and other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from Arcadia’s stockholders in connection with the proposed transactions. Information regarding the officers and directors of Arcadia is included in Arcadia’s most recent Annual Report on Form 10-K, as amended, filed with the SEC, including any information incorporated therein by reference, its definitive proxy statement for its 2024 annual meeting filed with the SEC on May 16, 2024, and in the Registration Statement initially filed with the SEC on February 14, 2025 and as amended July 31, 2025, and any amendments thereto as filed with the SEC. Additional information regarding such persons, as well as information regarding Roosevelt’s directors, managers and officers and other persons who may be deemed participants in the proposed transaction, will be set forth in the Registration Statement and proxy statement/prospectus, and any amendments thereto, and other materials, when they are filed with the SEC in connection with the proposed transaction. Free copies of these documents may be obtained from the sources indicated above.
Arcadia Biosciences Contact:
T.J. Schaefer
ir@arcadiabio.com
FAQ
What were Arcadia Biosciences (RKDA) Q2 2025 earnings results?
How did Zola coconut water perform for RKDA in Q2 2025?
What happened with RKDA's note receivable from Above Food?
What is the status of RKDA's merger with Roosevelt Resources?
How much did RKDA reduce its liabilities in 2025?
